Researchers have shown promising results on the ability of human embryonic stem cells to aid
in treatment of spinal cord injuries, blindness, Parkinson's disease, diabetes, muscular dystrophy, heart disease, and more.
The discovery of this «immune system paralysis» and its underlying mechanisms represents an important step on the path to improving
the treatment of spinal cord injury patients.
Scientists developed a drug that allows axons to cross impenetrable barriers leading to
the treatment of spinal cord injuries.
By learning from the similarities and differences, researchers hope to find new leads in
the treatment of spinal cord injury.
If you are attending ISSCR 2017, you can attend the Asterias workshop, titled «Clinical Development of hESC - derived Oligodendrocyte Progenitors for
the Treatment of Spinal Cord injury» on June 13, 2017 at 10:45 am.
After all, nanomaterials currently represent our best hope for developing innovative strategies in
the treatment of spinal cord injuries».
Our current efforts relating to our pluripotent stem cell platform are focused on developing AST - OPC1 (hES cell - derived neural cells) for
the treatment of spinal cord injury and other neurodegenerative diseases, and AST - VAC2 (hES cell - derived immunotherapy) for cancer.
GRNOPC1, hESC - derived oligodendrocyte progenitor cells, have been assessed by Geron for
treatment of spinal cord injury.
«With two human trials already underway for
the treatment of spinal cord injuries and degenerative eye diseases, it is clear ethical embryonic stem cell research is beginning to bear fruit for the millions of Americans facing debilitating diseases and conditions,» DeGette said in a release.
At Howard Law, we will build your case by working with your medical team and other leading professionals in the care and
treatment of spinal cord injuries.